
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded slow release capsule containing methylphenidate hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved. Methylphenidate is a Schedule II controlled substance.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing methylphenidate are listed in capsule, tablet, solution, patch and suspension forms.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Methylphenidate hydrochloride is a Schedule II central nervous system stimulant taken by mouth, which a pharmacy may compound on a prescriber's order.
Methylphenidate hydrochloride is a central nervous system stimulant. It blocks the reuptake of the brain chemical messengers norepinephrine and dopamine, raising their levels between nerve cells. Manufactured forms include tablets, chewable tablets, oral solution, oral suspension, orally disintegrating tablets, and extended-release tablets and capsules, under names such as Ritalin, Methylin, Concerta, Ritalin LA, Aptensio XR, Jornay PM and Quillivant XR. The Ritalin tablet label lists treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and older and narcolepsy. Methylphenidate is a Schedule II controlled substance. A prescriber might order it compounded in a strength or form that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Methylphenidate labels carry a boxed warning for abuse, misuse and addiction: misuse can lead to a substance use disorder, overdose and death, with higher risk from higher doses or snorting or injecting. Store it securely and never share it. Do not use it with an MAO inhibitor or within 14 days of stopping one (risk of hypertensive crisis), or with a methylphenidate allergy. Other warnings: sudden death with structural heart disease, raised blood pressure and heart rate, psychosis or mania, prolonged painful erections, poor blood flow in fingers and toes, slowed growth in children, glaucoma and tics. It may reduce the action of blood pressure medicines, and halogenated anesthetics raise surgical risk. LactMed reports very low milk levels and says use is not a reason to stop breastfeeding. Get emergency help for chest pain, fainting or trouble breathing; for other side effects, talk to your prescriber or pharmacist.
Methylphenidate inhibits presynaptic reuptake of norepinephrine and dopamine (StatPearls); the label calls its therapeutic mode of action unknown. Absolute oral bioavailability is 22% for the d-enantiomer and 5% for the l-enantiomer, plasma protein binding is low (10% to 33%), and it is de-esterified, via carboxylesterase 1 per StatPearls, to ritalinic acid, which has little or no activity; most of an oral dose appears in urine. Labeled indications (Ritalin tablets): ADHD in patients 6 years and older and adults; narcolepsy. StatPearls lists off-label uses such as cancer-related fatigue, refractory depression in older adults and apathy in Alzheimer disease, which are not FDA-approved indications. The label calls for cardiac and tic screening before treatment; dosing is per prescriber. Monitor blood pressure, heart rate, growth in children, psychiatric symptoms and signs of misuse; StatPearls adds periodic CBC with differential. Methylphenidate is Schedule II. Under DEA rules, electronic prescribing of controlled substances is voluntary; the CMS EPCS Program considers prescribers compliant when at least 70% of qualifying Medicare Part D Schedule II to V prescriptions are electronic, with an automatic exception for 100 or fewer, and states may set their own requirements (Rhode Island, for example, requires electronic prescriptions for Schedule II to V).
Swallow the capsule whole with fluid. Do not crush, chew, divide or open it, and do not dissolve it in liquid, because that can release the full dose at once. Take it at the same times each day as your label directs. Slow release forms are not meant for feeding tubes; ask your pharmacist if you need a different form.
These are nonaqueous capsules, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in a closed container at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth